REFRACTORY CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Clinical trials for REFRACTORY CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE trials appear
Sign up with your email to follow new studies for REFRACTORY CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to knock out tough blood cancers
Disease control Recruiting nowThis study is testing a combination of four chemotherapy drugs (cladribine, idarubicin, cytarabine, and venetoclax) to see how well they work against aggressive forms of blood cancer, including acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), and chronic my…
Matched conditions: REFRACTORY CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Could removing metals from the body help fight leukemia?
Disease control Recruiting nowThis early-stage study is testing whether adding metal-detoxifying drugs to standard chemotherapy can help control acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Researchers want to see if lowering metal levels in the blood and bone marrow improves treatment res…
Matched conditions: REFRACTORY CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC